Adam Schafer MD, PhD

Adam Schafer, MD, PhD

Assistant Professor of Medicine

Dr. Adam Schafer joined WashU Medicine Division of Infectious Diseases as an Assistant Professor of Medicine in 2026. He specializes in clinical infectious diseases, intraabdominal infections, and antibiotic stewardship. While Dr. Schafer’s research has focused on the management of complicated intra-abdominal infections, optimization of antimicrobial therapy, and clinical outcomes, his other academic interests include drug development, global health, and viral hemorrhagic fevers. Dr. Schafer enjoys teaching medical students, residents and fellows with a focus on clinical reasoning and infectious diseases education.

In addition to his faculty position, Dr. Schafer is directing the Antibiotic Stewardship Program at Missouri Baptist Medical Center. In this role, he will help build the OPAT program.

Dr. Schafer received his medical degree from University of Illinois College of Medicine at Chicago. He then completed his residency at Indiana University and his fellowship at University of North Carolina. 

Related Links
Additional Titles
  • Director, Antibiotic Stewardship Program, Missouri Baptist Medical Center
Patients seen at

Missouri Baptist Medical Center
315 Ballas Road
St. Louis, MO 63131

Education
  • BS, Biochemistry: Indiana University, Indianapolis IN (2013)
  • MD and PhD: University of Illinois College of Medicine at Chicago, Chicago IL (2021)
  • Internal Medicine Residency: Indiana University, Indianapolis IN (2024)
  • Infectious Disease Fellowship: University of North Carolina, Chapel Hill NC (2026)
Board Certifications
  • American Board of Internal Medicine
  • American Board of Internal Medicine, Subspecialty of Infectious Diseases
Select Publications
  1. Gaisina IN, Peet NP, Wong L, Schafer AM, Cheng H, Anantpadma M, Davey RA, Thatcher GRJ, Rong L. Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. J Med Chem. 2020 Jul 9;63(13):7211-7225. doi: 10.1021/acs.jmedchem.0c00463. Epub 2020 Jun 17. PMID: 32490678; PMCID: PMC7671190.
  2. Schafer A, Cheng H, Xiong R, Soloveva V, Retterer C, Mo F, Bavari S, Thatcher G, Rong L. Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics. Antiviral Res. 2018 Sep;157:47-56. doi: 10.1016/j.antiviral.2018.07.003. Epub 2018 Jul 4. PMID: 29981374; PMCID: PMC6087678.
  3. Schafer A, Cheng H, Lee C, Du R, Han J, Perez J, Peet N, Manicassamy B, Rong L. Development of Potential Small Molecule Therapeutics for Treatment of Ebola Virus Disease. Curr Med Chem. 2018;25(38):5177-5190. doi: 10.2174/0929867324666171010141416. PMID: 29032747.
  4. Cui Q, Du R, Anantpadma M, Schafer A, Hou L, Tian J, Davey RA, Cheng H, Rong L. Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor. Viruses. 2018 Mar 27;10(4):152. doi: 10.3390/v10040152. PMID: 29584652; PMCID: PMC5923446.
  5. Han J, Perez J, Schafer A, Cheng H, Peet N, Rong L, Manicassamy B. Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance. Curr Med Chem. 2018;25(38):5115-5127. doi: 10.2174/0929867324666170920165926. PMID: 28933281; PMCID: PMC8735713.

Schafer A – Search Results – PubMed